Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination
– Memic’s Hominis® platform is the first and only FDA-authorized surgical robot that features miniature humanoid-shaped arms, with shoulder, elbow, and wrist joints, providing human level dexterity and 360-degree articulation
– Hominis’ small, compact, and mobile design occupies a minimal footprint at a significant cost advantage compared to available robotic technology
– The first FDA-authorized indication of Hominis is in women’s health, including benign hysterectomy via the transvaginal approach, which is known to offer less pain, lower infection rates, faster recovery, and no visible scarring
– The MedTech Acquisition Corporation management team and board of directors bring decades of medical device and surgical robotics commercialization experience
– The combined companies are valued at an estimated pro-forma equity value of more than $1 billion, assuming no redemptions by MedTech’s public stockholders
– The Company will have approximately $360 million in pro forma cash on the balance sheet, assuming no redemptions by public stockholders of MedTech, less transactional expenses and operational expenses through closing, to support ongoing commercialization in women’s healthcare and development of additional Hominis robot-assisted surgical applications
– The business combination is supported by a $76 million PIPE with participation from leading investors, including Bridger Healthcare, Ltd., The Kraft Group, Monashee Investment Management LLC, Pura Vida Investments, Wellington Management, Ken Langone, Peregrine Ventures, HighSage Ventures, and management and board members of MedTech
Memic Innovative Surgery Ltd. (“Memic”), a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, and MedTech Acquisition Corporation (MTAC) (“MedTech”), a publicly traded special purpose acquisition company (SPAC) focused on medical technology, including surgical robotics, today announced that they have entered into a definitive agreement for a business combination. Upon the closing of the transaction, the combined company will operate under the Memic name and Maurice R. Ferré, MD, an independent director of MedTech and current Chairman of the board of Memic, will become Executive Chairman of the combined company. Memic will apply to have its ordinary shares listed on The Nasdaq Stock Market, The business combination is expected to be completed in the fourth quarter of 2021.
Recommended AI News: Torry Harris Integration Solutions Wins The ‘Best DevOps Services Company’ Award
“We are pleased to reach a merger agreement with MedTech, which represents a significant opportunity to advance the robot-assisted surgery market in ways that, until now, have been unattainable,” said Dvir Cohen, co-founder and Chief Executive Officer of Memic. “We believe the Hominis platform has the potential to transform the way surgeons perform robot-assisted procedures, beginning with our currently FDA-authorized indications that include transvaginal benign hysterectomy. Our partnership with the MedTech team, which provides decades of collective experience in surgical robotics, is an important step in bringing our advanced technology to medical facilities and patients across the United States and the world. We look forward to entering the public markets and working together with MedTech in the next phase of our company’s journey.”
Recommended AI News: MiR Launches Two Powerful Autonomous Mobile Robots To Optimize All Logistics
“This agreement with Memic reflects the continued commitment of our management team and board of directors to deliver value to our stockholders,” said Chris Dewey, Chief Executive Officer of MedTech. “Following a comprehensive review of investment opportunities, we were impressed with the highly accomplished management team at Memic and its disruptive, minimally invasive, cost-effective Hominis system, which positions the Company well for substantial growth and profitability. We believe that Memic’s innovative technology, coupled with our team’s expertise in successfully commercializing medical device companies, has the potential to create significant value for stockholders in the years ahead.”
“We believe that the Hominis platform represents the most significant advancement in soft-tissue surgical robotics in recent decades and this agreement further validates how our technology is positioned to transform the surgical robotics sector,” said Maurice R. Ferré, MD, Co-founder of MAKO Surgical, Inc. “Hominis is able to perform robotic transvaginal techniques that were previously unfeasible, fulfilling a significant unmet need in women’s health, and we believe it has the potential to be applied to a broad range of indications in the future including general surgery.”
Recommended AI News: McDermott Bolsters Global Privacy And Cybersecurity Group In Washington
Comments are closed.